NeuraLight News
8 articles
New assessment tool for ALS based on abnormal eye movements
NeuraLights software platform, which evaluates eye movement abnormalities, could be used as an assessment tool for patients with amyotrophic lateral sclerosis (ALS), according to research published in the Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration journal. The use of the platform correlated with current gold-standard clinical assessments, making it a viable adjunct assessment tool. The technology can be implemented in clinical trials and also as part of a routine assessment for ALS patients.
Customers
NeuraLight is making neurological diagnostics more precise
NeuroSense Therapeutics and NeuraLight collaborate to detect ALS using AI CTech
NeuraLight, an Israeli company that develops biomarkers for neurological diseases, has announced a collaboration with NeuroSense Therapeutics to promote research on degenerative neurological diseases, including ALS. The collaboration involves monitoring patients and sharing data to improve diagnoses and the use of digital biomarkers. NeuraLight recently raised $25 million in funding and this collaboration marks their first clinical trial. ALS is an incurable neurodegenerative disease, and the collaboration aims to develop disease-modifying therapies. The collaboration is seen as a long-term partnership, with future studies planned for Alzheimers and Parkinsons diseases.
PartnersCustomers
NeuraLight secures $25 million in Series A
NeuraLight, an Israeli startup developing precision medicine for neurological diseases using computer vision and smartphones, has raised $25 million in a Series A funding round. The round was led by Koch Disruptive Technologies, with participation from Breyer Capital, Samsung NEXT, VSC Ventures, and Viz.ai co-founders Chris Mansi and David Golan. The company plans to use the new capital to improve the design of neurological clinical trials, increase the probability of success for novel neurological therapeutics, and usher in a new era of precision medicine for neurology.
Investment
NeuraLight appoints Dr. Gil Shklarski as Scientific Co-founder and Board Observer
NeuraLight, a company specializing in digitizing neurological insights using AI, has appointed Dr. Gil Shklarski as Scientific Co-founder and Board Observer. Dr. Shklarski, who previously served as CTO of Flatiron Health, will help NeuraLight in its growth phase from Seed to Series A. He believes in the potential of NeuraLights team and technology to transform the lives of people with neurological disorders. NeuraLight launched in October 2021 with a $5.5 million investment co-led by MSAD.vc, Kli Capital, and Tuesday Capital. Dr. Shklarski will work closely with management to define the strategic playbook and execute the commercial aspects as the company prepares for its first clinical trials.
Management ChangesInvestment
The answer to Parkinson's and Alzheimer's is all in your eyes
Tel Aviv and Austin-based startup Neuralight has launched with a $5.5 million seed investment. The company aims to digitize and automate neurological evaluation and care by developing a technology that can decode data from the eyes. Neuralights platform extracts microscopic eye movement measurements that serve as digital endpoints for neurological disorders. The company plans to sell the data to pharmaceutical companies to accelerate drug development. Neuralights technology has the potential to make drug development for neurological diseases more effective. The company is in conversations with three large pharma companies and hopes to receive FDA clearance by the end of 2022.
InvestmentExpand
NeuraLight Raises $5.5M in Seed Funding - FinSMEs
NeuraLight, a company treating neurological disorders by digitizing neurology care, has raised $5.5 million in seed funding. The funding will be used to enhance the lives of people suffering from neurological disorders by digitizing neurological evaluation and care. NeuraLight uses proprietary Computer Vision and Deep Learning algorithms to capture objective and sensitive digital markers to help accelerate drug development and increase the success rates of new drugs. The platform can be integrated into clinical trials and remote settings, improving the patient experience. The companys team includes industry experts and advisors from the pharmaceutical and healthcare sectors.
Investment
How can startups leverage controversial FDA approval for Alzheimer's drug?
The FDAs approval of Biogens Alzheimers drug, Aducanumab, presents a significant opportunity for neurology-focused startups to address the challenges in the field. Neurological disorders affect over one billion people worldwide, and the lack of objective measurements has hindered progress in the field. Startups have successfully leveraged AI and machine learning in other medical disciplines, but neurology has lagged behind. The approval of Aducanumab highlights the need for objective and sensitive measurements in neurological drug development. Startups have the potential to introduce novel technologies and biomarkers that can revolutionize neurological treatment. By utilizing advanced computer vision, machine learning, and innovative approaches, startups can provide continuous monitoring and predictive models for neurological disorders. This presents a growth-positive opportunity for companies like NeuraLight, which aims to digitize neurology and transform the lives of people with neurological disorders.
InvestmentExpand
